Yaqiong Tian*1, Zengli Zhang†1, Liyun Miao*, Zhimin Yang‡, Jie Yang*, Yinhua Wang§, Danwen Qian¶,
Hourong Cai*, Yongsheng Wang*
Oncology Research, Vol.24, No.5, pp. 295-303, 2016, DOI:10.3727/096504016X14648701447814
Abstract Recently, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have revolutionized nonsmall cell lung cancer (NSCLC) treatment. However, resistance remains a major obstacle. Anexelekto (AXL)
is a member of receptor tyrosine kinases (RTKs) and shares the same downstream signaling pathways with
EGFR, such as PI3K/AKT and MAPK/ERK. AXL overexpression in resistant tumors has been implicated in
many previous studies in vitro and in vivo. In this study, we further examined whether expression of AXL and its
downstream targets increased in gefitinib-resistant PC9 cells (PC9GR). In addition, we hypothesize that knocking down AXL in PC9GR and… More >
Login
Register
